Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • SWB Online-Katalog
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

Primary Helicobacter pylori Eradication Rates of Lansoprazole, Amoxicillin, and Metronidazole Therapy is Much Higher than Lansoprazole, Amoxicillin and Clarithromycin Therapy in Chiba Prefecture, Japan

So Sakamoto, Shunji Fujimori and Fumio Sakamoto

Aim: To compare the efficacy of primary Helicobacter pylori eradication therapy between PPI/AC therapy (proton-pump inhibitor; lansoprazole, amoxicillin, and clarithromycin) and PPI/AM therapy (lansoprazole, amoxicillin, and metronidazole).

Methods: The subjects were patients with Helicobacter pylori infection who received initial eradication treatment at a family doctor in Katori City, Japan. Infection of Helicobacter pylori was initially evaluated pathologically using gastric mucosal specimens obtained by biopsy through upper endoscopy. Ninety-two patients underwent PPI/AC therapy and 28 patients underwent PPI/AM for primary eradication. Success or failure of eradication was determined by a urea breath test, and the primary eradication rates were compared between the two therapies. Patients who underwent PPI/AC but failed to achieve eradication were recommended to undergo secondary eradication treatment with PPI/AM, and the secondary eradication rate was assessed.

Results: In primary eradication therapy, successful eradication rates were 79.3% (73/92) in PPI/AC and 96.4% in PPI/AM, indicating that PPI/AM had a significantly higher eradication success rate (P=0.034). The 19 patients who failed to achieve eradication by PPI/AC underwent secondary eradication by PPI/AM. All 19 cases showed effective eradication (100%). Ultimately, eradication was successful in 99.2% (119/120) patients. Successful eradication rate in the total of primary and secondary PPI/AM treatments was also significantly higher than primary PPI/AC (46/47 vs. 73/92: P=0.007). Neither therapy was associated with any notable side effects.

Conclusion: In this regional study, PPI/AM therapy showed a favorable eradication rate, significantly higher than PPI/AC therapy. Thus, PPI/AM therapy is recommended as the primary eradication therapy in the region.